Infectious disease doctor Dr. Amesh Adalja on several states see spike in coronavirus cases.
A monoclonal antibody cocktail developed by Regeneron and Roche dropped the risk of symptomatic COVID-19 by up to 76% after three days for recently infected individuals not yet experiencing symptoms, according to a press release posted Monday. The drug, REGEN-COV, also significantly reduced duration of symptoms and lowered viral levels, Regeneron said.
REGEN-COV, comprised of casirivimab with imdevimab, has already received emergency use authorization from the FDA in the U.S. Under the current EUA, the combo therapy is approved to treat non-hospitalized adults and adolescents with mild to moderate symptoms of COVID-19 and who are at high risk for developing severe symptoms or the need for hospitalization.
Published: Apr 12, 2021
TARRYTOWN, N.Y., April 12, 2021 /PRNewswire/
REGEN-COV rapidly protected household contacts from exposure to SARS-CoV-2 at home, with 72% protection against symptomatic infections in the first week, and 93% in subsequent weeks
Among individuals who developed symptomatic infections, REGEN-COV recipients cleared the virus faster and had much shorter symptom duration
Regeneron will share data with U.S. FDA and request EUA expansion to include COVID prevention for appropriate populations, using a 1,200 mg subcutaneous dose
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive results from a Phase 3 trial (2069A) assessing the ability of REGEN-COV™ (casirivimab with imdevimab) to reduce the risk and burden of COVID-19 infection among household contacts of SARS-CoV-2 infected individuals. The trial, which was jointly run with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (
Regeneron Pharmaceuticals (NASDAQ: REGN) announced Monday that it is prepared to ask the Food and Drug Administration for approval to use its Covid-19 antibody therapy as a preventative treatment.
Study investigates the efficacy of COVID-19 vaccines over longer term news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.
Loading video.
VIDEO: UC San Diego students can participate in a nationwide clinical trial to assess how well a COVID-19 vaccine prevents infection and reduces risk of transmission. Watch this video to learn. view more
Credit: UC San Diego Health Sciences
COVID-19 vaccines were designed to reduce the likelihood that infection by the SARS-CoV-2 virus would lead to severe outcomes, such as hospitalization and death. In that sense, all of the currently approved vaccines Moderna, Pfizer and Johnson & Johnson have proven comparably effective.
But much less is known about the actual ability of these vaccines to prevent infection, most notably asymptomatic cases in which vaccinated persons might not become ill or display symptoms, but could still carry sufficient levels of the virus to pose a potential transmission threat to others.